Catabasis Pharmaceuticals, which is developing combined therapies for Duchenne muscular dystrophy and high cholesterol, raised $60 million by offering 5 million shares (upsized from 4.3 million shares) at $12, below the range of $13 to $15. Catabasis Pharmaceuticals plans to list on the NASDAQ under the symbol CATB. Catabasis Pharmaceuticals initially filed confidentially on 1/23/2015. Citi, Cowen & Company, Oppenheimer & Co. and Wedbush PacGrow acted as lead managers on the deal.
